{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Target intact parathyroid hormone (iPTH) values were within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.","groups":[{"description":"Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)","id":"OG000","title":"End-stage Kidney Disease With Secondary Hyperparathyroidism"}],"paramType":"NUMBER","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants Achieving Target Intact Parathyroid Hormone (iPTH) Levels at Month 6","type":"SECONDARY","unitOfMeasure":"participants"}